In a report published Wednesday, Jefferies analyst Corey Davis reiterated a Buy rating on Forest Laboratories FRX, and raised the price target from $43.00 to $48.00.
In the report, Jefferies noted, “In an effort to avert a 3rd proxy battle, FRX announced a new, Carl Icahn-designated board member. In exchange, Icahn has agreed to vote his ~12% stake in support of the full board as well as to certain, undisclosed standstill provisions. While this could deflate expectations for a potential FRX sale in the near term, we think little was in the stock and expect shares to continue to trade on strong fundamentals. Raising PT to $48.”
Forest Laboratories closed on Tuesday at $41.03.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.